Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-04-01

Clinical Trial Update: PS-341 Followed by Removal of Prostate for Those With Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of PS-341 (bortezomib) followed by prostate removal in prostate cancer patients has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Velcade (bortezomib)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Prostate Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2014-04-01